Sökning: "Glioblastoma"
Visar resultat 11 - 15 av 144 avhandlingar innehållade ordet Glioblastoma.
11. Brain Tumor Imaging and Treatment Effects. Imaging findings and cognitive function in glioblastoma patients
Sammanfattning : AbstractBackground: Glioblastoma is the most common malignant brain tumor. Operation with maximal resection, if feasible, otherwise biopsy followed by radiotherapy and chemotherapy with temozolomide is standard therapy. The prognosis remains poor, with median overall survival being 15 months despite therapy. LÄS MER
12. Integrative Modeling of Epigenetic Regulation in Human Disease
Sammanfattning : Glioblastoma is the most common and aggressive primary brain tumor. Standard of treatment prove ineffective, leading to tumor recurrence and an average survival rate of 14 months. This treatment resistance is attributed to both inter-tumor and intra-tumor heterogeneity observed across diverse tumor samples and within individual cells. LÄS MER
13. Modeling and investigations of high-grade glioma to understand tumorigenesis and heterogeneity
Sammanfattning : Glioblastoma (GBM) is the most common primary malignant brain tumor. As per 2021 WHO classification, the corresponding diagnosis in children is called diffuse pediatric-type high-grade glioma (pHGG). In both cases tumors are histone 3 (H3) and isocitrate dehydrogenase 1/2 (IDH1/2) wildtype (wt). LÄS MER
14. Modeling glioblastoma heterogeneity to decipher its biology
Sammanfattning : Glioblastoma multiforme (GBM) is the most common and lethal form of primary brain tumor that mainly affects adults. GBM displays remarkable intra- and inter-tumoral heterogeneity and contains a subpopulation of cells named glioma stem cells that is believed to be responsible for tumor maintenance, progression and recurrence. LÄS MER
15. New targeted therapies for malignant neural tumors : From systematic discovery to zebrafish models
Sammanfattning : Cancers in the neural system presents a major health challenge. The most aggressive brain tumor in adults, glioblastoma, has a median survival of 15 months and few therapeutic options. High-risk neuroblastoma, a childhood tumor originating in the sympathetic nervous system, has a 5-year survival under 50%, despite extensive therapy. LÄS MER